

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Jun 2026

Investigating the therapeutic effect of curcumin-peperin supplementation on metabolic syndrome, and liver fibrosis and steatosis indicators in bariatric surgery candidates: a randomized controlled trial.

Protocol summary

Study aim

Determining the therapeutic effects of curcumin-piperine supplementation on the indicators of metabolic syndrome, and liver fibrosis and steatosis in patients who are candidates for bariatric surgery.

Design

A controlled, parallel-group, triple-blind, randomized, phase 2 clinical trial on 110 patients. For randomization, special randomization sites such as sealed envelope are used.

Settings and conduct

A three-way blind controlled study will be conducted on bariatric surgery candidates with inclusion criteria, by giving a capsule containing 500 mg of curcumin and 5 mg of piperine to the intervention group and a placebo to the control group, for 8 weeks.

Participants/Inclusion and exclusion criteria

Patients with morbid obesity referred to the bariatric surgery clinic and met the inclusion criteria
Entry requirements - Patients with morbid obesity and candidates for bariatric surgery in the age range of 18 to 65 years - Diagnosis of metabolic syndrome based on tests -Diagnosis of metabolically dysfunction-associated fatty liver disease (MASLD) through ultrasound, biochemical and clinical analyses
Willingness to cooperate in the project and No allergy to curcumin or turmeric
Non-entry conditions - Regular consumption of multivitamin-mineral supplements and consumption of herbal extracts such as silymarin during the last 3 months - Diagnosed pathological conditions effective on the body - History of gastrointestinal diseases, autoimmunity and various malignancies

Intervention groups

Patients with morbid obesity referred to the bariatric surgery clinic and met the inclusion criteria

Main outcome variables

The amount of changes in metabolic syndrome

indicators: anthropometric analysis, biochemical analysis (FBS, HbA1c, Insulin, TG, LDL, HDL), systolic and diastolic blood pressure and Examining changes in the degree of hepatic steatosis or fibrosis

General information

Reason for update

Following approval of the changes to the proposal by the Research Committee of the Clinical Nutrition Department of Mashhad University of Medical Sciences, this update was made based on the amendment to the proposal.

Acronym

IRCT registration information

IRCT registration number: **IRCT20231116060076N1**

Registration date: **2023-11-30, 1402/09/09**

Registration timing: **prospective**

Last update: **2025-06-01, 1404/03/11**

Update count: **2**

Registration date

2023-11-30, 1402/09/09

Registrant information

Name

Mohadeseh Hassan zadeh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 51 3882 7034

Email address

hasanzadehm4001@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-12-11, 1402/09/20
Expected recruitment end date
2024-09-21, 1403/06/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Investigating the therapeutic effect of curcumin-peperin supplementation on metabolic syndrome, and liver fibrosis and steatosis indicators in bariatric surgery candidates: a randomized controlled trial.

Public title
Investigating the therapeutic effect of curcumin-peperin supplementation on metabolic syndrome, and liver fibrosis and steatosis

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Patients with morbid obesity and candidates for bariatric surgery in the age range of 18 to 65 years Diagnosis of metabolic syndrome by a specialist physician based on biochemical and clinical analyses Diagnosis of metabolically dysfunction-associated fatty liver disease (MASLD) through ultrasound, biochemical and clinical analyses by a specialist physician Willingness to cooperate in the project No known allergies to curcumin or turmeric
Exclusion criteria:
Regular consumption of multivitamin-mineral supplements, antioxidants, and omega-3 supplements in amounts exceeding the daily requirement, probiotic supplements, and consumption of herbal extracts such as silymarin during the past 3 months. Diagnosed pathological conditions affecting the liver such as types of viral hepatitis and liver transplantation History of gastrointestinal diseases, organ failure, thyroid disorders, kidney diseases, autoimmune diseases, severe mental diseases and types of malignancy.

Age
From **18 years** old to **65 years** old

Gender
Both

Phase
2

Groups that have been masked

- Participant
- Investigator
- Data analyser

Sample size
Target sample size: **110**

Randomization (investigator's opinion)
Randomized

Randomization description
Block randomization with blocks of 4 and 6 will be done using special randomization sites such as sealed

envelopes. After specifying the codes, each code is written separately on a sheet. Each sheet is placed in a separate envelope or folded and glued in such a way that it cannot be seen inside (allocation concealment). After obtaining informed consent, a sheet will be removed from each qualified patient and according to the code written in it, people will be placed in two study groups.

Blinding (investigator's opinion)

Triple blinded

Blinding description

The patient receives the drug (intervention or control group) in sealed envelopes that are coded. Coding is done by one of the collaborators of the project and the patient, researcher and analyst are blinded.

Placebo

Used

Assignment

Parallel

Other design features

In this study, food intake using a 24-hour food recall questionnaire and physical activity using the international IPAQ questionnaire will be examined as confounding variables before the intervention and 6 months after surgery.

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Mashhad University of Medical Sciences

Street address

Qureshi Building, University Street, Mashhad, Khorasan Razavi

City

mashhad

Province

Razavi Khorasan

Postal code

۱۳۹۲۴ ۹۱۳۸۸

Approval date

2023-09-23, 1402/07/01

Ethics committee reference number

IR.MUMS.MEDICAL.REC.1402.318

Health conditions studied

1

Description of health condition studied

Metabolic syndrome, liver fibrosis and steatosis

ICD-10 code

E88.8, K74

ICD-10 code description

Metabolic syndrome, Hepatic fibrosis, Hepatic steatosis,

Primary outcomes

1

Description

Fasting plasma glucose

Timepoint

Measurements will be taken at the beginning of the study (before the intervention), at the end of the intervention, and 6 months after surgery.

Method of measurement

Blood test using a laboratory assay

2

Description

2. Triglyceride

Timepoint

Measurements will be taken at the beginning of the study (before the intervention), at the end of the intervention, and 6 months after surgery.

Method of measurement

Blood test using a laboratory assay

3

Description

High Density Lipoprotein (HDL)

Timepoint

Measurements will be taken at the beginning of the study (before the intervention), at the end of the intervention, and 6 months after surgery.

Method of measurement

Blood test using a laboratory assay

4

Description

Blood Pressure

Timepoint

Measurements will be taken at the beginning of the study (before the intervention), at the end of the intervention, and 6 months after surgery.

Method of measurement

Mercury sphygmomanometer

5

Description

Anthropometric measurements

Timepoint

Measurements will be taken at the beginning of the study (before the intervention), at the end of the intervention, and 6 months after surgery.

Method of measurement

Height will be measured without shoes, with an accuracy of 0.5 cm, using a caliper. Weight, BMI, and waist-to-hip ratio will be measured using a bioelectrical impedance analyzer.

6

Description

Degree of hepatic steatosis or fibrosis

Timepoint

Measurements will be taken at the beginning of the study (before the intervention), at the end of the intervention, and 6 months after surgery.

Method of measurement

Liver elastography will be performed before the intervention and 6 months after surgery. Also, a liver biopsy will be performed at the end of the intervention (during surgery).

Secondary outcomes

1

Description

Liver enzymes (ALT, AST, ALP)

Timepoint

All variables will be measured at the beginning of the study (before the intervention), at the end of the intervention, and 6 months after surgery.

Method of measurement

Blood test using a laboratory assay

2

Description

Checking insulin resistance based on the HOMA-IR formula

Timepoint

All variables will be measured at the beginning of the study (before the intervention), at the end of the intervention, and 6 months after surgery.

Method of measurement

It will be measured by collecting a fasting blood sample at any time point and measuring fasting blood insulin and glucose levels using the formula $HOMA-IR = [Fasting\ Glucose\ (mg/dL) \times Fasting\ Insulin\ (mU/L)] / 405$.

Intervention groups

1

Description

Intervention group: includes 55 morbidly obese patients who are candidates for bariatric surgery and who meet the study entry criteria, who will be given a daily supplement containing 500 mg of curcumin and 5 mg of piperine for 8 weeks.

Category

Treatment - Drugs

2

Description

Control group: It includes 55 patients with morbid obesity and candidates for bariatric surgery who meet the inclusion criteria and will be given a placebo daily for 8 weeks.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Outpatient bariatric surgery clinic of Imam Reza Hospital

Full name of responsible person

Reza Rezvani

Street address

Imam Reza Hospital, Imam Reza Square

City

Mashhad

Province

Razavi Khorasan

Postal code

91137630067

Phone

+98 51 3802 2000

Email

Hasanzadehm4001@mums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Reza Rezvani

Street address

Department of Nutrition, Faculty of Medicine, Ferdowsi University Campus, Azadi Square

City

M,ashhad

Province

Razavi Khorasan

Postal code

9177948564

Phone

+98 51 3882 7034

Email

mds.nutrition@mums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Mohadeseh Hassan zadeh

Position

PhD candidate

Latest degree

Master

Other areas of specialty/work

Nutrition

Street address

Department of Nutrition, Faculty of Medicine, Ferdowsi University Campus, Azadi Square

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948564

Phone

+98 51 3882 7034

Email

hasanzadehm4001@mums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Reza Rezvani

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Department of Nutrition, Faculty of Medicine, Ferdowsi University Campus, Azadi Square

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948564

Phone

+98 51 3882 7034

Email

RezvaniR@mums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Mohadeseh Hassan zadeh

Position

PhD candidate

Latest degree

Master

Other areas of specialty/work

Nutrition

Street address

Department of Nutrition, Faculty of Medicine,
Ferdowsi University Campus, Azadi Square

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948564

Phone

+98 51 3882 7034

Email

hasanzadehm4001@mums.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available